Relationships Between Growth Factors (Somatomedin-C and Growth Hormone) and Body Development, Metabolic Control, and Retinal Changes in Children and Adolescents With IDDM

We used the radioimmunoassay (RIA) method to determine somatomedin-C (SmC) basal values in 59 diabetic children and adolescents (20 prepubertal and 39 pubertal subjects; age range 2.75–20.16 yr; duration of diabetes 0.08–15.83 yr) and in 274 control subjects. In comparing diabetic subjects with controls, we considered only those 50 diabetic subjects who were age matched with the controls, i.e., those not over 16 yr chronological age. SmC basal levels in pubertal diabetic patients were no different from those of pubertal age-matched control children, whereas in prepubertal diabetic patients SmC was significantly lower than in the respective control children (P < .001). No correlation was found between the z score for SmC (i.e., the number of standard deviations each SmC level is from the age- and sex-normalized mean) and duration of disease, velocity standard deviation score, severity of fluoroangiographic retinal changes, basal C-peptide values and HbA, levels. No differences were encountered in mean SmC and SmC z-score values in the separate groups of poorly, fairly, and well-controlled diabetic children, in the groups with and without residual pancreatic activity, and in the group with and without retinal changes. In 16 of the pubertal diabetics and in 15 pubertal controls, serum glucose, growth hormone (GH), and SmC concentrations were determined during the night. The integrated nocturnal secretion of SmC was no different in diabetics than in controls, whereas the integrated nocturnal secretion of GH was significantly (P < .025) higher in diabetics than in controls. These data suggest a partial block in somatomedin production, which would be compensated by a hypersecretion of GH through a negative-feedback relationship. On the other hand, it may be that GH hypersecretion is primary and that the normal or low SmC secretion is a response to low-efficiency GH.

[1]  S. Zucchini,et al.  Differences in somatomedin-C between short-normal subjects and those of normal height. , 1985, The Journal of pediatrics.

[2]  A. Kassoff,et al.  Von Willebrand Factor (VIII R: Ag), Fibronectin, and Insulin-like Growth Factors I and II in Diabetic Retinopathy and Nephropathy , 1984, Diabetes.

[3]  E. Froesch,et al.  Insulin-like growth factors. Studies in diabetics with and without retinopathy. , 1983, The New England journal of medicine.

[4]  T. Dornan,et al.  PLASMA SOMATOMEDIN ACTIVITY AND DIABETIC RETINOPATHY , 1983, Clinical endocrinology.

[5]  J. M. Horner,et al.  Growth hormone and somatomedin in insulin-dependent diabetes mellitus. , 1981, The Journal of clinical endocrinology and metabolism.

[6]  R L Hintz,et al.  Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. , 1981, The New England journal of medicine.

[7]  R L Hintz,et al.  Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. , 1981, Science.

[8]  J. V. Van Wyk,et al.  Somatomedin-C and the assessment of growth. , 1980, Pediatric clinics of North America.

[9]  K. Hall,et al.  Somatomedin A levels in serum from healthy children and from children with growth hormone deficiency or delayed puberty. , 1980, Acta endocrinologica.

[10]  L. Phillips,et al.  Somatomedin Activity and Diabetic Control in Children with Insulin-Dependent Diabetes , 1979, Diabetes.

[11]  H. Nash.  Growth failure, somatomedin and growth hormone levels in juvenile diabetes mellitus--a pilot study. , 1979, Australian and New Zealand journal of medicine.

[12]  T. Merimee.  A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. , 1978, The New England journal of medicine.

[13]  R. Furlanetto,et al.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. , 1977, The Journal of clinical investigation.

[14]  D. Rye,et al.  Somatomedin on insulin-dependent diabetes mellitus. , 1977, The Journal of clinical endocrinology and metabolism.

[15]  A. Prader,et al.  Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism. , 1976, The Journal of pediatrics.

[16]  L. Phillips,et al.  The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. , 1976, Endocrinology.

[17]  P. Passa,et al.  Influence of muscular exercise on plasma level of growth hormone in diabetics with and without retinopathy. , 1974, Lancet.

[18]  H. Oka,et al.  Radioimmunoassay of human proinsulin C-peptide using synthetic human connecting peptide. , 1974, Endocrinologia japonica.

[19]  J. Birkbeck.  Growth in juvenile diabetes mellitus , 1972, Diabetologia.

[20]  H. Ranney,et al.  Hemoglobin components in patients with diabetes mellitus. , 1971, The New England journal of medicine.

[21]  T. Olsen,et al.  Diabetes, diabetic angiopathy, and growth hormone. , 1970, Lancet.

[22]  Z. Laron,et al.  Pituitary dwarfism with high serum levels of growth hormone. , 1968, Israel journal of medical sciences.

[23]  G. M. Guest.  The Mauriac Syndrome: Dwarfism, hepatomegaly and obesity with juvenile diabetes mellitus , 1953, Diabetes.

[24]  A. Rogol,et al.  Effect of testosterone on somatomedin-C concentrations in prepubertal boys. , 1984, The Journal of clinical endocrinology and metabolism.

[25]  R. Suskind,et al.  Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. , 1978, The Journal of pediatrics.

[26]  D. S. Krishnamurthy.  GROWTH IN DIABETIC CHILDREN , 1974 .